| scholarly article | Q13442814 |
| P50 | author | David Flockhart | Q23563106 |
| Zeruesenay Desta | Q87723626 | ||
| P2093 | author name string | Lang Li | |
| Phuong D Nguyen | |||
| Anil Modak | |||
| Yasuhisa Kurogi | |||
| Suzanne M Lemler | |||
| P2860 | cites work | Clinical significance of the cytochrome P450 2C19 genetic polymorphism | Q28201086 |
| The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans | Q28254348 | ||
| Biochemistry and molecular biology of the human CYP2C subfamily | Q28299258 | ||
| Clinical relevance of genetic polymorphisms in the human CYP2C subfamily | Q28362533 | ||
| Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin | Q32156812 | ||
| Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study | Q34009506 | ||
| Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies | Q34430052 | ||
| Thalidomide metabolism by the CYP2C subfamily. | Q34523961 | ||
| CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor | Q34583603 | ||
| Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population | Q35803786 | ||
| Review article: immediate-release proton-pump inhibitor therapy--potential advantages | Q36319531 | ||
| Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population | Q36535932 | ||
| Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype | Q36684887 | ||
| Stereoselective disposition of proton pump inhibitors | Q37136970 | ||
| Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole | Q41128197 | ||
| A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants | Q42168063 | ||
| Identification and functional characterization of new potentially defective alleles of human CYP2C19. | Q44237764 | ||
| Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution | Q44538625 | ||
| Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil | Q44573290 | ||
| Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test | Q44854701 | ||
| Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability | Q44897887 | ||
| Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis | Q44973876 | ||
| Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations | Q46141212 | ||
| The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics | Q46758734 | ||
| The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype | Q46922848 | ||
| Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. | Q51901597 | ||
| Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects | Q60018974 | ||
| Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients | Q61945694 | ||
| Direct determination of pantoprazole enantiomers in human serum by reversed-phase high-performance liquid chromatography using a cellulose-based chiral stationary phase and column-switching system as a sample cleanup procedure | Q71553628 | ||
| Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation | Q72545136 | ||
| Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole--a preliminary study | Q73204570 | ||
| Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world | Q73257076 | ||
| Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype | Q74058615 | ||
| Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer | Q77732655 | ||
| CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans | Q77788807 | ||
| Liver disease selectively modulates cytochrome P450--mediated metabolism | Q80212249 | ||
| Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma | Q80709728 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breathing | Q9530 |
| P304 | page(s) | 297-305 | |
| P577 | publication date | 2009-01-09 | |
| P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| P1476 | title | Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test | |
| P478 | volume | 329 |
| Q37628680 | (13)C breath tests in personalized medicine: fiction or reality? |
| Q36808111 | A rapid non invasive L-DOPA-¹³C breath test for optimally suppressing extracerebral AADC enzyme activity - toward individualizing carbidopa therapy in Parkinson’s disease |
| Q35023701 | Addressing phenoconversion: the Achilles' heel of personalized medicine |
| Q38560254 | Alternative Sampling Strategies for Cytochrome P450 Phenotyping. |
| Q38122635 | Breath tests to phenotype drug disposition in oncology |
| Q96588883 | Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19 and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19 |
| Q40471212 | Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. |
| Q82468735 | Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood |
| Q36653603 | Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity? |
| Q34093850 | Role of the ¹³C-methacetin breath test in the assessment of acute liver injury in a rat model |
| Q35537682 | Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity |
| Q43116214 | [13C]pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel |
Search more.